

# MULTIPLE SCLEROSIS (MS) DRUGS AND BIOLOGICS: TECHNOLOGIES AND GLOBAL MARKETS



PHM069B  
June 2014

Yogita Zutshi  
*Project Analyst*

ISBN: 1-56965-870-6

**bcc** | Research  
Market Forecasting

**BCC Research**  
49 Walnut Park, Building 2  
Wellesley, MA 02481 USA  
866-285-7215 (toll-free within the USA),  
or (+1) 781-489-7301  
[www.bccresearch.com](http://www.bccresearch.com)  
[information@bccresearch.com](mailto:information@bccresearch.com)

## TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	2
STUDY GOALS AND OBJECTIVES	2
REASONS FOR DOING THIS STUDY	2
INTENDED AUDIENCE	3
SCOPE OF REPORT	3
METHODOLOGY	3
INFORMATION SOURCES	4
ANALYST'S CREDENTIALS	4
RELATED BCC RESEARCH REPORTS	4
BCC RESEARCH WEBSITE	4
DISCLAIMER	4
CHAPTER 2 SUMMARY	6
<i>SUMMARY TABLE A GLOBAL MARKET FOR MS DISEASE-MODIFYING PRODUCTS, THROUGH 2018 (\$ MILLIONS)</i>	7
<i>SUMMARY FIGURE GLOBAL MARKET FOR THERAPIES TREATING MS, 2011-2018 (\$ MILLIONS)</i>	7
<i>SUMMARY TABLE B GLOBAL MARKET FOR MS DISEASE-MODIFYING THERAPIES, BY REGION, THROUGH 2018 (\$ MILLIONS)</i>	8
CHAPTER 3 OVERVIEW	10
DISEASE CHARACTERISTICS	10
HISTORY AND DISCOVERY OF MS	10
SYMPTOMS OF MS	11
PREVALENCE AND INCIDENCE OF MS	11
<i>TABLE 1 MS STATISTICS FROM AROUND THE WORLD, 2013</i>	12
DIAGNOSIS OF MS	12
TYPES OF MS	14
PROGNOSIS	15
TREATMENTS FOR MS	15
TYPES OF MS THERAPIES	15
<i>TABLE 2 CURRENTLY APPROVED MS THERAPIES ON THE MARKET</i>	16
<i>TABLE 3 FEATURES OF SMALL MOLECULE VERSUS BIOLOGIC MS DISEASE-MODIFYING THERAPIES</i>	17
<i>TABLE 4 WHOLESALE ACQUISITION COST OF SELECTED THERAPIES FOR MS, 2013 (\$ MILLIONS)</i>	18
TARGETS OF MS THERAPIES	18
VLA-4 (CD49D AND CD29)	18
S1P	19
CD20	19
IL-2 (CD25, CD122 AND CD132)	19
MYELIN BASIC PROTEIN-REACTIVE T-CELLS	20
SIDE EFFECTS OF MS THERAPIES	20
<i>TABLE 5 COMPARISON OF SIDE-EFFECT PROFILES OF MARKETED AND LATE-CLINICAL STAGE THERAPIES FOR MS</i>	20
MS THERAPIES IN CLINICAL DEVELOPMENT	21
<i>TABLE 6 MS THERAPIES IN CLINICAL TRIALS, ORDERED BY PHASE</i>	21

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>TABLE 7 MS THERAPIES IN DEVELOPMENT, BY PHASE</i>	22
<i>TABLE 8 MS THERAPIES IN ACTIVE CLINICAL TRIALS BY PRIMARY TARGET</i>	23
<i>TABLE 9 COMPANIES WITH MORE THAN ONE MS THERAPY IN ACTIVE CLINICAL TRIALS OR ON THE MARKET</i>	23
CLINICAL TRIAL EFFICACY OUTCOME MEASUREMENTS IN MS STUDIES	23
Relapse Rate	24
EDSS	24
Gadolinium-enhanced (GdE) Lesions on MRI	24
<i>TABLE 10 EFFICACY RESULTS OF MS DISEASE-MODIFYING THERAPIES</i>	25
CHAPTER 4 TECHNOLOGY	27
OVERVIEW	27
<i>TABLE 11 GLOBAL SALES OF MS DISEASE-MODIFYING THERAPIES BY FORMULATION, THROUGH 2018 (\$ MILLIONS)</i>	27
<i>TABLE 12 ADMINISTRATION PROFILES OF THERAPIES APPROVED TO TREAT MS</i>	28
CHAPTER 5 PATENT EVALUATION	30
PATENT LENGTH AND MARKET EXCLUSIVITY	30
ORPHAN DRUG EXCLUSIVITY	30
<i>TABLE 13 U.S. PATENT EXPIRATION DATES OF THERAPIES FOR MS ON THE MARKET OR IN PHASE III DEVELOPMENT</i>	31
<i>TABLE 14 PATENT APPLICATIONS</i>	32
<i>TABLE 15 ISSUED PATENTS</i>	47
<i>TABLE 16 PATENT ASSIGNEES (NUMBER OF PATENTS)</i>	56
CHAPTER 6 SMALL MOLECULE MS DRUGS	64
MARKET OVERVIEW	64
<i>TABLE 17 GLOBAL MARKET FOR SMALL MOLECULE MS DISEASE-MODIFYING DRUGS BY INDIVIDUAL DRUG, THROUGH 2018 (\$ MILLIONS)</i>	64
SMALL MOLECULE MS DISEASE-MODIFYING DRUGS	65
COPAXONE (GLATIRAMER ACETATE, COPOLYMER 1)	65
<i>TABLE 18 COPAXONE PIVOTAL STUDY RESULTS</i>	66
NOVANTRONE (MITOXANTRONE)	67
GILENYA (FINGOLIMOD, FTY720)	68
<i>TABLE 19 GILENYA PIVOTAL PHASE III STUDY RESULTS</i>	69
AUBAGIO (TERIFLUNOMIDE)	70
<i>TABLE 20 AUBAGIO PHASE III STUDY RESULTS FROM TEMSO AND TEMPO</i>	70
TECFIDERA (DIMETHYL FUMARATE)	70
<i>TABLE 21 TECFIDERA GLOBAL PHASE III CLINICAL PROGRAM</i>	71
FIRATEGRAST (SB683699, T-0047)	72
SIPONIMOD (BAF312)	73
ONO-4641	73
ACT-128800	73
MASITINIB	74
TRIMESTA (ESTRIOL)	74
MN-166	75
CHAPTER 7 BIOLOGICS FOR MS	77

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>TABLE 22 GLOBAL MARKET FOR BIOLOGICS FOR MS BY INDIVIDUAL DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	77
<i>TABLE 23 BIOLOGICS FOR MS BY CLASS</i>	77
MABS ANTIBODIES FOR MS	78
<i>TABLE 24 BENEFITS AND CHARACTERISTICS OF MABS</i>	78
<i>TABLE 25 SELECTED ANTIBODIES IN DEVELOPMENT FOR MS</i>	79
TYSABRI (NATALIZUMAB)	79
<i>TABLE 26 TYSABRI SENTINEL AND AFFIRM STUDY RESULTS</i>	80
ZENAPAX (DACLIZUMAB)	81
<i>TABLE 27 DACLIZUMAB CHOICE STUDY RESULTS</i>	83
OCRELIZUMAB (RG1594)	84
ARZERRA (OFATUMUMAB)	84
AIN457	85
LY2127399	85
BIIB033	86
INTERFERON BETAS	86
BETASERON, BETAFERON (INTERFERON BETA-1B, BAY86-5046)	87
<i>TABLE 28 TWO-YEAR BETASERON RRMS STUDY RESULTS</i>	88
<i>TABLE 29 THREE-YEAR BETASERON RRMS STUDY RESULTS</i>	89
AVONEX (INTERFERON BETA-1A)	89
<i>TABLE 30 AVONEX PIVOTAL PHASE III STUDY RESULTS</i>	90
REBIF (INTERFERON BETA-1A)	91
EXTAVIA (INTERFERON BETA-1B)	92
CINNOVEX (INTERFERON BETA-1A)	93
PEG INTERFERON BETA-1A (BIIB017)	93
THERAPEUTIC VACCINES	94
TCELNA (FORMERLY KNOWN AS TOVAXIN)	95
ATX-MS-1467	95
RTL1000	96
BHT-3009	96
ATL1102 (FORMERLY TV-1102)	97
<b>CHAPTER 8 DISEASE APPLICATIONS</b>	99
OVERVIEW	99
<i>TABLE 31 LABELS OF APPROVED DISEASE MODIFYING THERAPIES FOR MS</i>	100
MS SUBGROUPS	103
RRMS	103
SPMS	103
PPMS	104
PRMS	105
THE MARKET FOR MS THERAPIES BY MS DISEASE SUBGROUP CLASSIFICATION	105
<b>CHAPTER 9 COMPANY PROFILES</b>	107
AB SCIENCE	107
AB SCIENCE USA	107
ABBVIE	107
ACORDA THERAPEUTICS INC.	108
ACTELION	108

<b>TOPIC</b>	<b>PAGE NO.</b>
ACTIVE BIOTECH	109
ANTISENSE THERAPEUTICS	109
APITOPE	110
ARTIELLE IMMUNOTHERAPEUTICS	111
BAYER AG	111
BAYER (U.S. LOCATION)	111
BAYHILL THERAPEUTICS	112
BIOGEN IDEC	113
CINNAGEN	114
DAIICHI SANKYO	114
ELI LILLY	115
FAST FORWARD LLC	115
FIVE PRIME THERAPEUTICS	116
GENMAB	116
GENMAB (U.S. LOCATION)	116
GENZYME	117
GLAXOSMITHKLINE	117
GLAXOSMITHKLINE (U.S. LOCATION)	118
GW PHARMACEUTICALS	118
INNATE IMMUNOTHERAPEUTICS	118
AUSTRALIAN OFFICE	118
NEW ZEALAND OFFICE	119
MEDICINOVA	119
MERCK KGAA (MERCK SERONO)	120
MITSUBISHI TANABE PHARMA	120
NOVARTIS	121
ONO PHARMA	121
OPEXA THERAPEUTICS	122
PFIZER	122
ROCHE	123
SANOFI-AVENTIS	123
SYNTHETIC BIOLOGICS	124
TEVA PHARMACEUTICAL INDUSTRIES	124
CHAPTER 10 INTERNATIONAL ASPECTS AND REGULATORY ISSUES	126
MARKET BY REGION	126
<i>TABLE 32 GLOBAL FORECAST FOR MS DISEASE-MODIFYING THERAPIES BY REGION, THROUGH 2018 (\$ MILLIONS)</i>	126
UNITED STATES	127
The FDA Modernization Act of 1997	127
Fast-Track Status	127
Special Protocol Assessments	128
New Surveillance and Safety Requirements	128
Approvable Letters	129
Consumer Confidence	129
Medicare	130
Other Healthcare Changes	130
EUROPEAN UNION	131

<b>TOPIC</b>	<b>PAGE NO.</b>
New Drug Approvals and Innovation	131
Drug Reimbursement and Reference Pricing	132
Relocation of R&D	133
JAPAN	133
New Drug Approvals	133
Regulatory Climate	134
Relationship between Academia and Industry	135
CHAPTER 11 FUTURE DIRECTIONS	137
UNMET NEED STILL REMAINS HIGH	137
PATENT EXPIRIES AND PRICING PRESSURE MAY RESTRAIN THE MARKET GROWTH	137
DEVELOPMENT OF TREATMENT OPTIONS FOR THE PROGRESSIVE FORMS OF MS HAS THE POTENTIAL TO EXPAND AND GROW THE MARKET	138
THE ROLE OF BIOMARKERS AND PHARMACOGENOMICS	139
COMBINATION THERAPIES	140

**LIST OF TABLES**

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
SUMMARY TABLE A GLOBAL MARKET FOR MS DISEASE-MODIFYING PRODUCTS, THROUGH 2018 (\$ MILLIONS)	7
SUMMARY TABLE B GLOBAL MARKET FOR MS DISEASE-MODIFYING THERAPIES, BY REGION, THROUGH 2018 (\$ MILLIONS)	8
TABLE 1 MS STATISTICS FROM AROUND THE WORLD, 2013	12
TABLE 2 CURRENTLY APPROVED MS THERAPIES ON THE MARKET	16
TABLE 3 FEATURES OF SMALL MOLECULE VERSUS BIOLOGIC MS DISEASE-MODIFYING THERAPIES	17
TABLE 4 WHOLESALE ACQUISITION COST OF SELECTED THERAPIES FOR MS, 2013 (\$ MILLIONS)	18
TABLE 5 COMPARISON OF SIDE-EFFECT PROFILES OF MARKETED AND LATE-CLINICAL STAGE THERAPIES FOR MS	20
TABLE 6 MS THERAPIES IN CLINICAL TRIALS, ORDERED BY PHASE	21
TABLE 7 MS THERAPIES IN DEVELOPMENT, BY PHASE	22
TABLE 8 MS THERAPIES IN ACTIVE CLINICAL TRIALS BY PRIMARY TARGET	23
TABLE 9 COMPANIES WITH MORE THAN ONE MS THERAPY IN ACTIVE CLINICAL TRIALS OR ON THE MARKET	23
TABLE 10 EFFICACY RESULTS OF MS DISEASE-MODIFYING THERAPIES	25
TABLE 11 GLOBAL SALES OF MS DISEASE-MODIFYING THERAPIES BY FORMULATION, THROUGH 2018 (\$ MILLIONS)	27
TABLE 12 ADMINISTRATION PROFILES OF THERAPIES APPROVED TO TREAT MS	28
TABLE 13 U.S. PATENT EXPIRATION DATES OF THERAPIES FOR MS ON THE MARKET OR IN PHASE III DEVELOPMENT	31
TABLE 14 PATENT APPLICATIONS	32
TABLE 15 ISSUED PATENTS	47
TABLE 16 PATENT ASSIGNEES (NUMBER OF PATENTS)	56
TABLE 17 GLOBAL MARKET FOR SMALL MOLECULE MS DISEASE-MODIFYING DRUGS BY INDIVIDUAL DRUG, THROUGH 2018 (\$ MILLIONS)	64
TABLE 18 COPAXONE PIVOTAL STUDY RESULTS	66
TABLE 19 GILENYA PIVOTAL PHASE III STUDY RESULTS	69
TABLE 20 AUBAGIO PHASE III STUDY RESULTS FROM TEMSO AND TEMPO	70
TABLE 21 TECFIDERA GLOBAL PHASE III CLINICAL PROGRAM	71
TABLE 22 GLOBAL MARKET FOR BIOLOGICS FOR MS BY INDIVIDUAL DRUGS, THROUGH 2018 (\$ MILLIONS)	77
TABLE 23 BIOLOGICS FOR MS BY CLASS	77
TABLE 24 BENEFITS AND CHARACTERISTICS OF MABS	78
TABLE 25 SELECTED ANTIBODIES IN DEVELOPMENT FOR MS	79
TABLE 26 TYSABRI SENTINEL AND AFFIRM STUDY RESULTS	80
TABLE 27 DACLIZUMAB CHOICE STUDY RESULTS	83
TABLE 28 TWO-YEAR BETASERON RRMS STUDY RESULTS	88
TABLE 29 THREE-YEAR BETASERON RRMS STUDY RESULTS	89
TABLE 30 AVONEX PIVOTAL PHASE III STUDY RESULTS	90
TABLE 31 LABELS OF APPROVED DISEASE MODIFYING THERAPIES FOR MS	100
TABLE 32 GLOBAL FORECAST FOR MS DISEASE-MODIFYING THERAPIES BY REGION, THROUGH 2018 (\$ MILLIONS)	126

**LIST OF FIGURES**

<b>FIGURE TITLE</b>	<b>PAGE NO.</b>
SUMMARY FIGURE GLOBAL MARKET FOR THERAPIES TREATING MS, 2011-2018 (\$ MILLIONS)	7